Overview of Daiphen

Quick Facts

Property	Description
Active Ingredients	Sulfamethoxazole, Trimethoprim
Form	Tablet, Oral Suspension, Intravenous Solution
Pharmacological Class	Antimicrobial Agent (Broad-spectrum antibiotic)
Common Use	Targeting bacterial infection
Origin	Synthetic Drug

What is Daiphen and What Pharmacological Class Does it Belong To?

Daiphen is a trade name for the synthetic drug known as Co-trimoxazole, an antimicrobial agent used to target and eliminate harmful bacteria. It is classified as a broad-spectrum antibiotic within the chemotherapeutic agent class. This prescription-only medication is recognized for its clinical use in treating a variety of infections. The combination of Sulfamethoxazole and Trimethoprim is classified as an antifolate agent, which works against a wide range of bacteria. The drug functions by interrupting the essential nutrient processes of microbial threats. Unlike single-component medications, Daiphen is a fixed-dose combination (FDC).

What is the Composition of Daiphen and Why is it a Combination Drug?

The drug is composed of two distinct active ingredients: Sulfamethoxazole and Trimethoprim. Sulfamethoxazole belongs to the Sulphonamide class, while Trimethoprim is categorized as a Diaminopyrimidine. This combination therapy is manufactured for systemic administration in multiple pharmaceutical preparations, including the solid Tablet, an Oral suspension for liquid dosing, and a sterile Intravenous solution (IV solution) for parenteral delivery. This pairing is central to the drug's identity, as the interaction between these two distinct chemical classes results in an increase in overall antibacterial activity. The combined action is more potent than if the components were utilized individually.

What is the General Purpose of Daiphen?

The general purpose of Daiphen is to eliminate harmful bacteria and stop the progression of bacterial infection throughout the body. Its effectiveness is based on the synergistic effect, where the two ingredients work together to achieve a more powerful bactericidal action than either could accomplish alone. It is commonly used for addressing infections in the urinary and respiratory tracts. This is achieved through a Sequential Blockade that prevents bacteria from generating the folic acid necessary for their survival and reproduction, making Daiphen an effective tool against systemic infection.

Regulatory References

Co-trimoxazole: MedlinePlus Drug Information

What side effects are possible with Daiphen?

Possible side effects and safety information

The safety profile for Daiphen (Co-trimoxazole) is defined by adverse reactions categorized by frequency and the physiological systems affected, as documented in official regulatory sources like the FDA and EMA. The incidence of adverse effects is classified into frequency tiers:

Very Common (occurring in 10% or more of patients): Hyperkalaemia (elevated blood potassium levels).
Common (1% to 10%): Nausea, Diarrhoea, Headache, and Rash. Fungal overgrowth is also documented in this category.

System-Organ-Class Safety Groupings

Adverse reactions are formally grouped by the system affected, including Blood and Lymphatic System Disorders (associated with potentially severe blood dyscrasias like thrombocytopenia and various anemias), Skin and Subcutaneous Tissue Disorders (including rash and photosensitivity), Gastrointestinal Disorders, and Hepatobiliary Disorders (including jaundice and hepatic necrosis).

Serious Adverse Reactions and Restrictions

Very Rare (less than 0.01%) but critical adverse reactions include severe cutaneous events such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as Fulminant Hepatic Necrosis and severe blood disorders like Agranulocytosis. The risk for these serious skin reactions is noted to be highest during the first weeks of treatment.

Safety is population-specific: Older adults are more susceptible to severe side effects and Infants under two months of age are generally considered a contraindicated population. The medicine is also contraindicated in patients with a history of megaloblastic anaemia due to folate deficiency or severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Daiphen (Co-trimoxazole) overdosage is characterized by specific clinical findings and mandated emergency actions.

Documented Overdose Manifestations

Acute overdose presentations include gastrointestinal symptoms like nausea and vomiting, alongside neurological signs such as confusion, drowsiness, ataxia, and headache. Chronic overdosage is formally associated with blood dyscrasias and potential bone marrow depression.

Serious physiological outcomes documented in the overdose context include severe electrolyte disturbances like hyperkalemia and complications such as crystalluria and hyponatremia. Elderly patients and those with impaired kidney or liver function are noted to be more susceptible to severe effects, based on regulatory labeling.

Immediate Emergency Action

Regulators mandate that immediate medical attention must be sought if an overdose is suspected. Urgent help is required if the person is collapsed, experiencing a seizure, has trouble breathing, or cannot be awakened (unconsciousness). In these severe situations, contact emergency services immediately, or call the poison control helpline.

Official management procedures listed in the labeling are based on symptomatic and supportive treatment, including measures like gastric lavage and careful monitoring for electrolyte imbalances and hematologic status. Folinic Acid is the specific procedural step recommended to counteract hematological toxicity from chronic overdosage.

Therapeutic Uses of Daiphen

What Daiphen Treats: Main Uses and Benefits

Daiphen (Co-trimoxazole) is an antimicrobial agent commonly used to address susceptible bacteria in various infections throughout the body. Its primary role is to address the underlying bacterial cause, which generally supports the patient during difficult episodes by easing distress. The medication is commonly used to treat conditions involving acute or disruptive episodes across several domains.

Key Therapeutic Domains

Daiphen is applied across domains where additional symptomatic support is needed, and is commonly used in conditions presenting with acute episodes like bacterial infections of the urinary tract (including Pyelonephritis), the respiratory system (such as acute flare-ups of chronic bronchitis), and the gastrointestinal tract (including conditions like Traveler’s Diarrhea and Shigellosis). It is also considered relevant in specific high-risk scenarios, including the crucial preventative use (prophylaxis) against severe Opportunistic Infections (OIs), such as Pneumocystis jirovecii Pneumonia (PJP), particularly in immunosuppressed patients.

The medication is used for managing symptom clusters that create noticeable discomfort, such as painful urination (dysuria), severe cramping and diarrhea, and symptoms that interfere with daily functioning like acute breathing difficulty. This supportive relief generally supports patients during episodes of heightened discomfort.

“The primary benefit supports the patient during difficult episodes by easing distress and helping to manage the symptoms that interfere with routine activities.”

Quick Fact: Symptomatic Support in Acute Contexts
Symptom Cluster Focus	Pain, Fever, Dysfunctional Symptoms
Typical Context	Acute symptomatic episodes / Recurrent infections / Prophylaxis
Benefit Goal	Supports comfort and assists with maintaining functional stability

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Daiphen?

The population eligibility for Daiphen (Co-trimoxazole) is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated groups.

Populations Approved for Use

Daiphen is approved for use in adults and in pediatric patients 2 months of age and older. Use in these groups is subject to the absence of specific contraindications listed in the official labeling.

Absolute Contraindications

The medicine is contraindicated and must not be used by the following groups, as stated in regulatory documents:

Patients with known hypersensitivity to trimethoprim or sulfonamides.
Patients with marked hepatic damage or severe renal insufficiency (specifically CrCl < 15 mL/minute).
Patients with documented megaloblastic anemia due to folate deficiency.
Infants under 2 months of age.
Pregnant patients at term and nursing mothers.

Eligibility-Related Restrictions

Use is subject to caution or dose adjustment in certain populations. Older adults require particular care and close monitoring. Patients with CrCl 15 to 30 mL/min are eligible only under a restricted regimen. Caution is also required for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or certain metabolic disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Daiphen (Sulfamethoxazole/Trimethoprim) through several critical pharmacokinetic and pharmacodynamic mechanisms that dictate co-administration constraints.

Official Interaction Statements

Co-administration with Dofetilide is prohibited because the trimethoprim component inhibits renal cation transport, leading to increased plasma concentrations of Dofetilide and a severe risk of ventricular arrhythmias.

Potassium-Sparing Effects: Concurrent use with medicines that increase potassium, such as ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), or Potassium-sparing Diuretics, results in an increased risk of clinically relevant hyperkalaemia (elevated potassium levels).
Metabolic Inhibition: Daiphen can increase the exposure and potential toxicity of drugs with narrow therapeutic windows, notably Warfarin (by inhibiting its metabolism, leading to potentiation of anticoagulant activity) and Phenytoin (by prolonging its half-life).
Transporter Interference: The trimethoprim component increases plasma levels of Digoxin and Procainamide due to inhibition of renal tubular secretion.
Anti-Folate Effects: The drug has an additive anti-folate effect with medicines like Methotrexate and Pyrimethamine, which may increase the risk of haematological adverse reactions. Concurrent use of Leucovorin (for PJP treatment) is contraindicated due to documented increased mortality risk.
Supplements: Regulatory sources note that Para-Aminobenzoic Acid (PABA) supplements may reduce the antibacterial effectiveness of the sulfamethoxazole component.

Mechanism of Action

Sequential Blockade of Microbial Folate Synthesis

The mechanism of action for Daiphen (Co-trimoxazole) is defined by the synergism of its two components, Sulfamethoxazole and Trimethoprim, which execute a double interference strategy on the bacterial folate biosynthesis pathway. Sulfamethoxazole acts as a competitive inhibitor of the enzyme Dihydropteroate synthase (DHPS) by mimicking its natural substrate, Para-aminobenzoic acid (PABA). Sequentially, Trimethoprim inhibits the enzyme Dihydrofolate reductase (DHFR). This Sequential Blockade halts the formation of the co-factor, Tetrahydrofolic acid (THF), by stopping two essential, consecutive steps.

Disruption of Bacterial Genetic Material

The resulting cellular consequence is the depletion of THF co-factors, which are required for the synthesis of purine and pyrimidine bases. This deficit directly and irreversibly disrupts Nucleic Acid Synthesis, specifically halting the ability of the microbial cell to build DNA or RNA, preventing its division and repair. This cascade from dual enzyme inhibition to genetic failure results in a bactericidal effect, which is the key physiological consequence of the drug's action, targeting microbial metabolism selectively.

Dosage and Administration Information

How Daiphen is Used: Official Dosing and Administration

This section outlines the instructions for the administration and standardized dosage of Daiphen (Co-trimoxazole), consistent with its classification as an antimicrobial agent. All details on use are based on standardized prescribing information.

Approved Routes and Dosage Forms

Daiphen is approved for systemic administration via two primary routes:

Oral Route (PO): The most common route, available as Tablets (Single Strength/SS and Double Strength/DS: 160 mg Trimethoprim (TMP) / 800 mg Sulfamethoxazole (SMX)) and Oral Suspension.
Intravenous Route (IV): Used for severe infections or when oral administration is not feasible, available as a sterile Intravenous Solution.

Standard Dosing Regimens and Frequency

The standard adult oral dosage for conditions like uncomplicated urinary tract infections (UTIs) and acute bronchitis is typically one Double Strength (DS) Tablet.

Indication	Standard Adult Oral Dosing (DS Tablet)	Frequency	Duration of Use
Urinary Tract Infections (UTIs)	1 DS tablet	Every 12 hours	10 to 14 days
Traveler's Diarrhea / Shigellosis	1 DS tablet	Every 12 hours	5 days
PJP Prophylaxis (Prevention)	1 DS tablet	Once daily	Varies

Administration Conditions and Adjustments

Oral doses may be taken without regard to meals but should be consumed with a full glass of water. The intravenous solution must be diluted prior to use and administered as an infusion over 60 to 90 minutes; rapid injection is not permitted.

Dose adjustments are mandatory for patients with impaired renal function. If the patient's Creatinine Clearance (CrCl) is between 15 and 30 mL/min, the usual dosage regimen must be halved. The use of Daiphen is generally not recommended for children under two months of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Daiphen (Co-trimoxazole)

This section provides an overview of the existing research landscape for Daiphen, describing what has been studied and what the available findings indicate about patterns observed during the research. The evidence is presented only to contextualize how symptoms and outcomes were tracked in study populations.

Evidence for Use in Acute Bacterial Infections

This area summarizes the structure of short-term Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated Daiphen in the research context of acute bacterial infections, specifically in the urinary tract (UTIs) and during acute flare-ups of chronic bronchitis (AECB).

Research on Acute Urinary Tract Infections (UTIs)

The research explored outcomes related to physical discomfort by measuring patterns of change classified as clinical endpoints (changes in symptoms such as painful urination) and the rate at which bacteria were cleared. Findings describe the patterns of symptom change and microbial clearance that were tracked and reported in the studies over the short term. The documented rise in antimicrobial resistance across many areas introduces uncertainty regarding the full applicability of historical study outcomes to the current patient population.

Research on Acute Exacerbations of Chronic Bronchitis (AECB)

The research examined outcomes related to functional imbalance by measuring the rate of clinical response (change in severity of respiratory symptoms), treatment failure, and the need for subsequent interventions during the acute episode. Findings describe patterns observed in the studies regarding symptom change. However, evidence quality varies across studies due to the difficulty in determining if the exacerbation is bacterial or non-bacterial. There is limited information for long-term outcomes or repeated use.

Evidence for Preventing and Treating Opportunistic Infections (PJP)

Research on Prophylaxis (Prevention) of PJP

The use of Daiphen in a research context where acute or disruptive episodes were monitored was studied in profoundly immunosuppressed patients through long-term cohort studies. The primary outcome monitored the occurrence of PJP infection over extended periods. Regulatory summaries describe patterns observed in the studies where the measured PJP occurrence was consistently tracked. What remains uncertain: Optimal dosing and duration of prevention are not fully established across all non-HIV immunocompromised patient groups.

What is Still Uncertain About Daiphen (Evidence Gaps)

The impact of increasing antimicrobial resistance on measured outcomes may mean that historical study results do not determine whether an individual will respond similarly today. Researchers note that long-term effects are not fully established across all indications, as follow-up durations were limited in many acute treatment trials. Findings describe group patterns, not personal outcomes; the research highlights what is known — and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Daiphen (FAQ)

Q: How quickly does Daiphen typically start working?

A: According to official product information, peak blood levels of the active ingredients typically occur 1 to 4 hours after the oral dose is taken. Official guidance indicates that steady-state concentrations (a consistent level in the body) are typically reached after about three days of taking the medicine.

Q: What happens if I miss a scheduled dose of Daiphen?

A: Official patient information generally advises skipping the missed dose if it is almost time for the next one, and not taking a double dose to compensate. If a dose is missed, it is usually recommended to take it as soon as it is remembered.

Q: Is it normal to feel a little dizzy when first starting Daiphen?

A: Official documents list side effects such as dizziness and headache. Regulatory safety advice often includes a general caution regarding activities that require alertness, as the medicine may cause dizziness or changes in awareness.

Q: Do I need to change my diet while I am taking Daiphen?

A: Oral doses of Daiphen can generally be taken without regard to meals, but official instructions mention taking the oral dose with a full glass of water. Additionally, regulatory warnings note that alcohol use is typically restricted during treatment due to the potential for a severe reaction.

Q: Is Daiphen known to cause weight gain or weight loss?

A: Regulatory adverse event reports list decreased appetite (anorexia) and weight loss as possible effects of the medicine. Weight gain is not commonly listed in official documents related to the drug's safety profile.

Q: Does Daiphen interact with alcohol?

A: Yes, regulatory warnings note that alcohol use is typically restricted during treatment and for a period after treatment is finished. This is due to the potential for a severe reaction, which can include flushing, nausea, and a rapid heartbeat.

Q: How long does Daiphen stay in your system after stopping it?

A: The mean serum half-lives of the drug's components are typically around 8 to 10 hours. While the drug is quickly processed, detectable amounts may be present in the blood for up to 24 hours after the last administration.

Q: Are there any specific activities to avoid while on Daiphen?

A: Official documents advise that caution is needed for activities that require high alertness, such as driving or operating machinery. This is a general safety warning noted due to the drug's potential to cause dizziness or changes in alertness.

Q: Is Daiphen a controlled substance or habit-forming?

A: Daiphen (Co-trimoxazole) is classified as a prescription-only antimicrobial agent in official regulatory documents. It is not listed as a controlled substance and has no known potential to be habit-forming.

Q: Can Daiphen affect the results of lab tests?

A: Yes, official regulatory lab information indicates that the medicine may affect the results of certain lab tests. Because of this potential interference, it is important to inform laboratory personnel and your healthcare provider that you are taking Daiphen.

Q: Is there a generic version of Daiphen available?

A: Yes, regulatory and official sources confirm that Daiphen is the brand name for the generic combination drug known universally as Co-trimoxazole (sulfamethoxazole and trimethoprim). The generic version is widely available.

Q: Can Daiphen be used during pregnancy?

A: Official product information states that the drug is contraindicated at term (near delivery). Its use during the first trimester has been associated with an increased risk of birth defects due to the drug’s interference with the body’s folate processes.

Q: What are the symptoms of an allergic reaction to Daiphen?

A: Signs of a serious hypersensitivity (allergic) reaction, as described in regulatory adverse event reports, may include a rash, itching, fever, sore throat, mouth sores, and difficulty breathing or swallowing.

Q: Where can I find the official prescribing information for Daiphen?

A: Official prescribing information is published and maintained by government regulatory bodies like the FDA (DailyMed). This factual content is also summarized in public health resources such as the NIH MedlinePlus.

Q: Does Daiphen interact with common vitamins or herbal products?

A: Official labeling notes that the medicine is known to interact with Para-Aminobenzoic Acid (PABA) supplements. Regulatory advice emphasizes that all vitamins, supplements, and herbal products should be disclosed to a healthcare professional.

Q: What are the official recommendations for stopping the use of Daiphen?

A: Official guidelines emphasize the importance of completing the full prescribed course of treatment, even if symptoms improve quickly. This guidance is provided to support the complete resolution of the underlying condition and to help prevent the development of drug resistance.

Q: Can Daiphen cause fatigue or changes in energy levels?

A: Yes, fatigue and insomnia (difficulty sleeping) are listed among the documented side effects of the medicine in official regulatory documents.

Q: Why is Daiphen not recommended for children?

A: The medicine is strictly contraindicated in infants under two months of age. This restriction is based on the theoretical risk of causing or worsening kernicterus (a type of brain damage) associated with high bilirubin levels in very young infants.

Q: What is the reasoning behind the specific warnings listed for Daiphen?

A: The reasoning for many warnings, such as the risk of blood disorders and kidney function changes, is tied to the drug's mechanism of action, which involves disrupting the folate pathway. Warnings also reflect how the medicine is primarily eliminated by the kidneys.

Q: Can Daiphen be taken alongside birth control pills?

A: Regulatory warnings state that this medicine may make hormonal birth control less effective. The warning indicates that patients using oral contraceptives may need to discuss alternative or backup methods with a healthcare professional.

Q: Are there any required tests before starting treatment with Daiphen?

A: Patients may be tested for G6PD deficiency before treatment due to the risk of anemia. Routine blood work and kidney function tests are commonly checked during the course of therapy. Monitoring for potential blood or kidney function changes may be part of the treatment plan.

Q: Does Daiphen affect sleep patterns?

A: Yes, insomnia (difficulty sleeping) is explicitly listed as a documented side effect of the medicine in official product safety documents.

Q: Are there any special considerations for people with diabetes using Daiphen?

A: Special caution is advised for patients with diabetes because official information indicates that Daiphen, when combined with certain diabetes drugs, may increase the risk of low blood sugar.

Q: What does the package insert say about driving or operating machinery while on Daiphen?

A: The official package insert typically includes a caution regarding driving or operating machinery. This is noted because the medication has the potential to cause side effects such as dizziness or confusion.

How should Daiphen be stored and disposed of?

How to Store and Dispose of Daiphen?

Daiphen must be stored precisely according to the labeled requirements to maintain its stability, strength, and purity. Store the medication below the maximum temperature specified on the original container (such as 25 C or 30 C) and protect it from moisture and light by keeping it in the original outer packaging. Do not use the medicine past its expiration date.

After first opening or reconstitution, adhere to the specific in-use stability period defined in the official labeling, if one is provided. It is mandatory to keep the medicine out of the sight and reach of children and pets at all times.

For disposal, the safest method for unused or expired Daiphen is a community drug take-back program or a mail-back service. If these options are unavailable, and the drug is not on the regulatory 'flush list,' mix the medication with an undesirable substance (like dirt or used coffee grounds), place it in a sealed bag or container, and discard it in household trash.

Daiphen